Search research articles
Contact Us
Filters
Showing results (151-160 of 175) with videos related to
Page
of 18
Sort By:
Neuro-Oncology
|
September 27, 2024
Long-term outcome of the Milano-hyperfractionated accelerated radiotherapy strategy for high-risk medulloblastoma, including the impact of molecular subtype
Maura Massimino, Francesco Barretta, Chiara Dossena, et al.
Neuro-Oncology
|
December 19, 2024
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial
Karsten Nysom, Lindsay B Kilburn, Sarah E S Leary, et al.
Cancer Cell
|
December 24, 2014
Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease
Rebecca M Hill, Sanne Kuijper, Janet C Lindsey, et al.
Journal of Medicinal Chemistry
|
May 14, 2014
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations
Ted W Johnson, Paul F Richardson, Simon Bailey, et al.
Journal of Medicinal Chemistry
|
December 28, 2020
Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)
Hengmiao Cheng, Suvi T M Orr, Simon Bailey, et al.
Neuro-Oncology Advances
|
December 31, 2025
An innovative virtual fellowship leveraging global and regional mentorship to foster pediatric neuro-oncologists in low/middle-income countries
Zeena Salman, Daniel C Moreira, Rahat Ul Ain, et al.
Journal of Medicinal Chemistry
|
March 14, 2017
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR
Simon Planken, Douglas C Behenna, Sajiv K Nair, et al.
Journal of Medicinal Chemistry
|
January 18, 2014
Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib
Qinhua Huang, Ted W Johnson, Simon Bailey, et al.
Nature Medicine
|
November 18, 2023
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
Lindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Journal of Neuro-Oncology
|
September 16, 2019
Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?
Fatma E El-Khouly, Sophie E M Veldhuijzen van Zanten, Vicente Santa-Maria Lopez, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 175) with videos related to
Sort By:
Page
of 18
Neuro-Oncology
|
September 27, 2024
Long-term outcome of the Milano-hyperfractionated accelerated radiotherapy strategy for high-risk medulloblastoma, including the impact of molecular subtype
Maura Massimino, Francesco Barretta, Chiara Dossena, et al.
Neuro-Oncology
|
December 19, 2024
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial
Karsten Nysom, Lindsay B Kilburn, Sarah E S Leary, et al.
Cancer Cell
|
December 24, 2014
Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease
Rebecca M Hill, Sanne Kuijper, Janet C Lindsey, et al.
Journal of Medicinal Chemistry
|
May 14, 2014
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations
Ted W Johnson, Paul F Richardson, Simon Bailey, et al.
Journal of Medicinal Chemistry
|
December 28, 2020
Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)
Hengmiao Cheng, Suvi T M Orr, Simon Bailey, et al.
Neuro-Oncology Advances
|
December 31, 2025
An innovative virtual fellowship leveraging global and regional mentorship to foster pediatric neuro-oncologists in low/middle-income countries
Zeena Salman, Daniel C Moreira, Rahat Ul Ain, et al.
Journal of Medicinal Chemistry
|
March 14, 2017
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR
Simon Planken, Douglas C Behenna, Sajiv K Nair, et al.
Journal of Medicinal Chemistry
|
January 18, 2014
Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib
Qinhua Huang, Ted W Johnson, Simon Bailey, et al.
Nature Medicine
|
November 18, 2023
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
Lindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Journal of Neuro-Oncology
|
September 16, 2019
Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?
Fatma E El-Khouly, Sophie E M Veldhuijzen van Zanten, Vicente Santa-Maria Lopez, et al.
Page
of 18